Pacira BioSciences, Inc. cash flow to debt ratio of 33.45% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Pacira BioSciences, Inc.'s free cash flow has decreased -23.55% from $178.75M last year to $136.66M, signaling decreasing performance

Pacira BioSciences, Inc.'s debt to equity ratio is 0.63, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Pacira BioSciences, Inc.'s debt has decreased relative to shareholder equity from 0.82 last year to 0.63 today, signaling strengthened financials

Pacira BioSciences, Inc. has a net debt to EBITDA ratio of 2.41x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Pacira BioSciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Pacira BioSciences, Inc.'s profit margin has increased (-104.92%) in the last year from -14.20% to 0.70%, signaling increasing performance

Pacira BioSciences, Inc.'s short-term assets of $547.97M exceed its short-term liabilities of $120.59M

Pacira BioSciences, Inc.'s return on assets of 0.43% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pacira BioSciences, Inc.'s return on equity of 0.73%, is lower than 15.00%, indicating bad performance

Pacira BioSciences, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Pacira BioSciences, Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings

Pacira BioSciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Pacira BioSciences, Inc. has a free cash flow yield of 13.89%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Pacira BioSciences, Inc.'s yearly earnings has increased -107.07% since last year from $-99.56M to $7.03M, signaling increasing performance

Pacira BioSciences, Inc.'s yearly revenue has increased 3.63% since last year from $700.97M to $726.41M, signaling increasing performance

ROIC 0.80% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Pacira BioSciences, Inc.'s 3-year revenue CAGR of 2.89% is positive, indicating growing revenue over the past 3 years

Pacira BioSciences, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Pacira BioSciences, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity

Pacira BioSciences, Inc. is undervalued relative to its fair value price of 49.51 based on Discounted Cash Flow model

Pacira BioSciences, Inc. has an earnings yield of 0.51%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Pacira BioSciences, Inc. is overvalued relative to its fair value price of 12.51 based on EBITDA multiple model

Pacira BioSciences, Inc. has an EV/EBITDA ratio of 10.45x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Pacira BioSciences, Inc. is overvalued relative to its fair value price of 19.13 based on Earnings Fair Value model

Pacira BioSciences, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.

Pacira BioSciences, Inc. has a price-to-book ratio of 1.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Pacira BioSciences, Inc. has a price-to-sales ratio of 1.38x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue